Harmony Biosciences Holdings, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $55.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors including Harmony Biosciences Holdings’ strong financial performance and promising pipeline developments. The company reported preliminary third-quarter 2025 net product revenue for WAKIX that significantly exceeded expectations, showing a 29% year-over-year increase and a 19% sequential rise. This robust performance led to an upward revision of the 2025 revenue guidance, further solidifying the company’s growth trajectory.
Additionally, Harmony’s pipeline is progressing well, with late-stage programs on track to achieve key milestones. The ongoing pivotal bioequivalence study for pitolisant gastro-resistant is expected to yield topline data by the fourth quarter of 2025, with a potential New Drug Application filing in 2026. Furthermore, the initiation of two Phase 3 trials for pitolisant high-dose in narcolepsy and idiopathic hypersomnia is anticipated to enhance the drug’s efficacy and labeling. These developments, alongside a valuation approach using discounted cash flow and sum-of-the-parts methodologies, support the Buy rating and a price target of $55.
In another report released today, Needham also maintained a Buy rating on the stock with a $41.00 price target.